STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 100 filers reported holding STOKE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.06 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $188,123 | -63.9% | 47,747 | -2.7% | 0.00% | -50.0% |
| Q2 2023 | $521,689 | +60.4% | 49,077 | +25.7% | 0.00% | +100.0% |
| Q1 2023 | $325,328 | -12.8% | 39,055 | -3.4% | 0.00% | -50.0% |
| Q4 2022 | $373,012 | +3.0% | 40,413 | +43.2% | 0.00% | 0.0% |
| Q3 2022 | $362,000 | -2.9% | 28,223 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $373,000 | -22.9% | 28,223 | +22.6% | 0.00% | 0.0% |
| Q1 2022 | $484,000 | +8.5% | 23,013 | +23.7% | 0.00% | 0.0% |
| Q4 2021 | $446,000 | -12.7% | 18,603 | -7.4% | 0.00% | 0.0% |
| Q3 2021 | $511,000 | -11.3% | 20,087 | +17.4% | 0.00% | -33.3% |
| Q2 2021 | $576,000 | – | 17,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $1,062,825,000 | 82.06% |
| RTW INVESTMENTS, LP | 3,544,248 | $219,495,000 | 3.68% |
| Cormorant Asset Management, LP | 1,437,807 | $89,043,000 | 2.12% |
| Redmile Group, LLC | 2,686,234 | $166,358,000 | 2.01% |
| ACUTA CAPITAL PARTNERS, LLC | 92,500 | $5,729,000 | 1.56% |
| Pinz Capital Management, LP | 34,200 | $2,118,000 | 0.96% |
| Birchview Capital, LP | 20,000 | $1,239,000 | 0.71% |
| HighVista Strategies LLC | 17,668 | $1,094,000 | 0.70% |
| GILDER GAGNON HOWE & CO LLC | 1,470,841 | $91,089,000 | 0.45% |
| Perceptive Advisors | 671,978 | $41,616,000 | 0.45% |